Importance of HPV Genotyping for the screening, therapy and management of cervical neoplasias

Geburtshilfe und Frauenheilkunde

Volumn 72, Issue 6, 2012, Pages 507-512

  Jentschke, M ^a   Soergel, P ^a   Hillemanns, P ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Cervical cancer; Cervical interepithelial neoplasia (CIN); Human papillomavirus

Indexed keywords

CANCER SCREENING; CARCINOGENICITY; DIAGNOSTIC ACCURACY; GENOTYPING TECHNIQUE; HUMAN PAPILLOMAVIRUS TYPE 16; PAPANICOLAOU TEST; PRECANCER; REVIEW; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION; WART VIRUS;

EID: 84863094420     PISSN: 00165751     EISSN: 14388804     Source Type: Journal    
DOI: 10.1055/s-0032-1314959     Document Type: Review

References (19)

1. Poljak M, Kocjan BJ. Commercially available assays for multiplex detection of alpha human papillomaviruses. Expert Rev Anti Infect Ther 2010;8:1139-1162
2. Meijer CJ, Berkhof J, Castle PE et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 2009;124:516-520
3. Naucler P, Ryd W, Tornberg S et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 2009;101:88-99
4. Bulkmans NW, Berkhof J, Rozendaal L et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007;370:1764-1772
5. Ronco G, Giorgi-Rossi P, Carozzi F et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010;11:249-257
6. Dillner J, Rebolj M, Birembaut P et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008;337:a1754
7. de Sanjose S, Quint WG, Alemany L et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010;11:1048-1056
8. Wheeler CM, Hunt WC, Joste NE et al. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst 2009;101:475-487
9. Castle PE, Schiffman M, Wheeler CM et al. Human papillomavirus genotypes in cervical intraepithelial neoplasia grade 3. Cancer Epidemiol Biomarkers Prev 2010;19:1675-1681
10. Khan MJ, Castle PE, Lorincz AT et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005;97:1072-1079
11. Schiffman M, Glass AG, Wentzensen N et al. A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20, 000 women in the Portland Kaiser cohort study. Cancer Epidemiol Biomarkers Prev 2011;20:1398-1409
12. Kjaer SK, Frederiksen K, Munk C et al. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 2010;102:1478-1488
13. Stoler MH, Wright jr. TC, Sharma A et al. High-risk human papillomavirus testing in women with ASC?US cytology: results from the ATHENA HPV study. Am J Clin Pathol 2011;135:468-475
14. Health Council of the Netherlands. Population screening for cervical cancer. Publication no. 2011/07. ISBN 978-90-5549-841-3. The Hague: 2011
15. Kitchener HC, Almonte M, Gilham C et al. ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening. Health Technol Assess 2009;13:1-150, iii-iv
16. Anttila A, Kotaniemi-Talonen L, Leinonen M et al. Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme. BMJ 2010;340:c1804
17. Bulkmans NW, Rozendaal L, Snijders PJ et al. POBASCAM, a populationbased randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44, 102 women. Int J Cancer 2004;110:94-101
18. Rijkaart DC, Berkhof J, Rozendaal L et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol 2012;13:78-88
19. Sankaranarayanan R, Nene BM, Shastri SS et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009;360:1385-1394